Enhanced Water-Soluble Cannabinoid and/or Terpene Extracts with Improved Bioavailability and Customizable Bulk Density

Publication ID: 24-11857589_0001_PTD

Published: October 28, 2025

Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Water-Soluble Cannabinoid and/or Terpene Extracts with Improved Bioavailability and Customizable Bulk Density,” Published Technical Disclosure No. 24-11857589_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857589_0001_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,589.

Summary of the Inventive Concept

This inventive concept presents a system, method, and composition for creating and utilizing water-soluble, powdered cannabinoid and/or terpene extracts with improved bioavailability, customizable bulk density, and enhanced delivery options.

Background and Problem Solved

The original patent disclosed a water-soluble, powdered cannabinoid and/or terpene extract, but it had limitations in terms of bioavailability and bulk density control. The new inventive concept addresses these limitations by introducing a pH-dependent release mechanism, mucoadhesive excipients, and a solvent-emulsifier combination, enabling improved absorption and customizable dosage forms.

Detailed Description of the Inventive Concept

The inventive concept comprises a system for creating water-soluble, powdered cannabinoid and/or terpene extracts using a solvent-emulsifier combination, which enables improved solubility and bioavailability. The method involves incorporating the extract into a pharmaceutical composition with a pH-dependent release mechanism, triggered by changes in pH in the gastrointestinal tract. The composition may include mucoadhesive excipients to enhance residence time in the gastrointestinal tract. Additionally, the process for preparing the extract involves solubilizing, mixing with emulsifiers, and spray-drying to form a powder with customizable bulk density.

Novelty and Inventive Step

The new claims introduce a pH-dependent release mechanism, mucoadhesive excipients, and a solvent-emulsifier combination, which are not present in the original patent. These novel elements enable improved bioavailability, customizable bulk density, and enhanced delivery options, thereby providing a non-obvious advancement over the prior art.

Alternative Embodiments and Variations

Alternative embodiments may include using different solvents, emulsifiers, or mucoadhesive excipients. Variations of the pharmaceutical composition may involve different pH-dependent release mechanisms or additional excipients to enhance bioavailability. The inventive concept could also be applied to other bioactive compounds beyond cannabinoids and terpenes.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and nutraceutical industries, particularly in the development of cannabis-based products with improved bioavailability and customizable dosage forms. Target markets may include companies focused on cannabis-based therapeutics, nutraceuticals, and wellness products.

CPC Classifications

Section	Class	Group
A	A61	A61K36/185
A	A61	A61K9/107
A	A61	A61K47/02
A	A61	A61K47/36
A	A61	A61K47/40
A	A61	A61K47/44

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical formulation and drug delivery systems, specifically focused on cannabinoid extraction, solubilization, and advanced delivery mechanisms with expertise in emulsification, spray-drying, and pharmaceutical composition design

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or chemical engineer with advanced degree, specialized knowledge in drug formulation techniques, experience with extraction processes, emulsification methods, and understanding of bioavailability enhancement strategies

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core technology, applying standard pharmaceutical formulation techniques to improve cannabinoid extract delivery. The proposed modifications involve well-known pharmaceutical engineering approaches like pH-dependent release mechanisms and mucoadhesive excipients, which are standard strategies for enhancing drug bioavailability and absorption. These incremental improvements would be considered routine optimization within the field of pharmaceutical formulation.

Obvious Combinations & Variations

Source Patent Element

Water-soluble, micronized, emulsified powdered cannabis extract complexed with cyclodextrin

PTD Variation

Adding pH-dependent release mechanism and mucoadhesive excipients to enhance gastrointestinal absorption

Obviousness Reasoning

Modifying drug delivery systems with pH-responsive and mucoadhesive components is a known technique for improving pharmaceutical bioavailability, representing a predictable variation within standard pharmaceutical engineering practices

Source Patent Element

Powdered extract loaded onto mesoporous silica

PTD Variation

Implementing spray-drying technique to create customizable bulk density powder

Obviousness Reasoning

Spray-drying is a standard pharmaceutical powder processing technique that allows precise control of particle characteristics, representing a routine design choice for a PHOSITA seeking to modify extract properties

Source Patent Element

Cannabis extract complexed with cyclodextrin

PTD Variation

Using solvent mixture of water and non-polar solvent with combined natural and synthetic emulsifiers

Obviousness Reasoning

Exploring different solvent and emulsifier combinations is a standard approach in pharmaceutical formulation for improving extract solubility and stability, representing an obvious variation to a skilled practitioner

Source Patent Element

Powdered cannabinoid extract

PTD Variation

Developing respirable powder for dry powder inhaler with specific particle size distribution

Obviousness Reasoning

Adapting pharmaceutical powders for alternative delivery routes is a common pharmaceutical engineering strategy, with particle size optimization being a predictable method of extending drug delivery capabilities

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857589 and the disclosed variations, a person having ordinary skill in the art would find the claimed pharmaceutical compositions and methods obvious, as the PTD represents routine optimization and predictable variations of known cannabinoid extract formulation techniques, thereby rendering subsequent claims involving similar technological approaches anticipated and non-patentable under 35 U.S.C. Section 103.

Original Patent Information

Patent Number	US 11,857,589
Title	Water-soluble, powdered cannabinoid and/or terpene extract
Assignee(s)	MEDPHARM HOLDINGS, LLC